Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BiRD (Clarithromycin, Lenalidomide, Dexamethasone) in Newly Diagnosed Multiple Myeloma
NCT00151203Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Dec 2004
- Primary completion
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide and clarithromycin in multiple myeloma (MM), sponsored by Weill Cornell Medicine. Primary endpoints: Response rate at 3 years, Time to maximum response at 3 years and 1 more. Started Dec 2004; status: completed.
02
Drugs
lenalidomideclarithromycin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00151203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00151203.